mp.weixin.qq.com· 蒲公英资讯·· 14 hours agoScore67
NMPA Approves AbbVie's Upadacitinib for Severe Alopecia Areata in China
艾伯维：乌帕替尼获批重度斑秃适应症
In brief
China's National Medical Products Administration has approved AbbVie's upadacitinib extended-release tablets for severe alopecia areata in adults and adolescents aged 12 and older, according to the regulator's website on October 15, 2026. The oral JAK1 inhibitor's approval rests on the Phase 3 UP-AA programme, two identically designed randomized, placebo-controlled, double-blind studies in adults and adolescents with severe alopecia areata.
Source: mp.weixin.qq.com · mp.weixin.qq.com